SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Global Wholehealth Partners Corp (CIK 0001598308) — Feb 2, 2021

Global Wholehealth Partners Corp (CIK 0001598308)
Date: Feb. 2, 2021 · CIK: 0001598308 · Accession: 0000000000-21-001325

AI Filing Summary & Sentiment

File numbers found in text: 333-252501

Date
February 2, 2021
Author
Not clearly detected
Form
UPLOAD
Company
Global Wholehealth Partners Corp (CIK 0001598308)

Letter

United States securities and exchange commission logo February 2, 2021 Charles Strongo Chief Executive Officer Global Wholehealth Partners Corporation 2227 Avenida Oliva San Clemente, California 92673 Re:Global Wholehealth Partners Corporation Registration Statement on Form S-1 Filed January 28, 2021 File No. 333-252501 Dear Mr. Strongo: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Kasey Robinson at 202-551-5880 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Stephen Mills, Esq.

Show Raw Text
United States securities and exchange commission logo
February 2, 2021
Charles Strongo
Chief Executive Officer
Global Wholehealth Partners Corporation
2227 Avenida Oliva
San Clemente, California 92673
Re:Global Wholehealth Partners Corporation
Registration Statement on Form S-1
Filed January 28, 2021
File No. 333-252501
Dear Mr. Strongo:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Kasey Robinson at 202-551-5880 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Stephen Mills, Esq.